Targeting Voltage-Gated Sodium Channels for Treating Neuropathic and Inflammatory Pain

Author(s): Charles J. Cohen

Journal Name: Current Pharmaceutical Biotechnology

Volume 12 , Issue 10 , 2011

Become EABM
Become Reviewer
Call for Editor


Voltage-gated sodium channels (NaV) are well validated targets for treating pain based both on human genetics and clinical experience. Consequently, there is an extensive literature on sodium channels for the treatment of pain and a number of excellent and thorough reviews have recently appeared; a selection of these is provided. This review does not attempt to evaluate all aspects of the studies in this area, but rather will focuses on several key issues that are incompletely addressed in prior reviews or that represent very recent additions to the literature. Key questions that arise are: 1) How much channel block is required to observe efficacy against neuropathic or inflammatory pain? 2) How can one improve upon the therapeutic index of previously tested NaV blockers?

Keywords: Analgesia, NaV, pain, voltage-gated sodium channel, channel block, efficacy, neuropathic or inflammatory pain, therapeutic index, ANALGESIC ACTIVITY, inflammed tissue, PET ligands

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Published on: 01 March, 2012
Page: [1715 - 1719]
Pages: 5
DOI: 10.2174/138920111798357249
Price: $65

Article Metrics

PDF: 23